CATALYST PHARMACEUTICALS, INC.(CPRX)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
CATALYST PHARMACEUTICALS, INC. (CPRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CPRX at 74.0/100 on a 32-signal composite quality model, placing it at rank #123 of 2,960 stocks — the top 5% of the AI-ranked universe. CPRX scores in the top quartile across balance sheet strength (96.6), profitability (93.7), free cash flow (87.8). Shareholder dilution risk is elevated at 27.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CATALYST PHARMACEUTICALS, INC. reports quarterly revenue of $149.4M, net income of $63.7M, an operating margin of 49.0%. Top institutional holders of CPRX by reported 13-F value include BlackRock, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CPRX trades on the Nasdaq exchange and files with the SEC under CIK 1369568. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CATALYST PHARMACEUTICALS, INC. directly from SEC EDGAR.
AI Quality Score
74.0/100
AI Rank
#123
Revenue
$149.4M
Net Income
$63.7M
Free Cash Flow
$59.6M
Operating Margin
49.0%
CPRX key financials by period
CATALYST PHARMACEUTICALS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K/A
$589.0M
$214.3M
43.8%
FY 2024
10-K
$491.7M
$163.9M
39.7%
FY 2023
10-K/A
$398.2M
$71.4M
21.8%
FY 2022
10-K
$214.2M
$83.1M
47.5%
FY 2021
10-K
$140.8M
$39.5M
37.2%
FY 2020
10-K
$119.1M
$75.0M
34.7%
Institutions holding CPRX
Institutional investors reporting a position in CATALYST PHARMACEUTICALS, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-05-11 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Total revenue rose 5.6% to $149.4M as FIRDAPSE (+18.1%) and AGAMREE (+66.6%) growth offset a 61.3% FYCOMPA collapse, while Catalyst agreed to be acquired by Angelini Pharma for $31.50 per share.
Biggest Revenue Drivers
Product revenue, net$149.3M+5.6% YoY
Primarily driven by increases in sales volumes for both FIRDAPSE and AGAMREE
License and other revenue$47 thousand+123.8% YoY
Consisted of royalties
Biggest Revenue Drivers
Total revenue: $149.4M+5.6% YoY
Product revenue, net$149.3M+5.6% YoY
Primarily driven by increases in sales volumes for both FIRDAPSE and AGAMREE
Within Product revenue, net
FIRDAPSE®$98.9M+18.1% YoY
Increase in sales volumes
AGAMREE®$36.7M+66.6% YoY
Increase in sales volumes
FYCOMPA®$13.8M-61.3% YoY
Generic entry following loss of exclusivity in 2025
License and other revenue$47 thousand+123.8% YoY
Consisted of royalties
Largest Expense Items
Selling, general and administrative$49.3M+5.1% YoY
Increase in general and administrative from consulting fees related to multiple business initiatives, including business development
Cost of sales$14.5M-19% YoY
Primarily a decrease in royalty obligations related to FIRDAPSE
Amortization of intangible assets$9.7M
FYCOMPA, RUZURGI and AGAMREE rights amortized straight-line over 5, 14.5 and 10.5 years
Research and development$2.7M-31.5% YoY
Research and clinical trial expense fell $0.9M, or 45.4%
Margins: Operating income rose to $73.2M from $63.4M as cost of sales fell to $14.5M on lower FIRDAPSE royalties; the overall upstream FIRDAPSE royalty rate dropped to 6% from a prior maximum of 18.5%.
Watch Items from the Filing
Pending merger with Angelini Pharma at $31.50 per share cash; a termination fee of approximately $155.5 million applies under specified circumstances.
Customer A represented 90.1% of total net product revenue, up from 74.0% a year earlier.
FYCOMPA revenue fell to $13.8M from $35.6M; the company expects further declines and ceased all marketing for the product at the end of 2025.
Hetero FIRDAPSE patent litigation settled with market entry no earlier than January 2035, but Catalyst owes an $11.0 million litigation avoidance fee in Q2 2026.
Effective tax rate rose to 24.3% from 20.4%; company also relies on Santhera as sole AGAMREE supplier while transitioning manufacturing by end of 2026.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
